权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Validation and Advanced Development of Glycan Node Analysis in Lung Cancer Research

肺癌研究中聚糖节点分析的验证和高级发展

基本信息

批准号：
8810396
负责人：
CHAD R BORGES
金额：
$ 31.77万
依托单位：
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-02-01 至 2017-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8810396
关键词：
Adenocarcinoma Advanced Development Age Agreement Antibodies Arizona Biological Biological Assay Biological Markers Blood Cancer Detection Cancer Patient Characteristics Classification Clinical Clinical Sensitivity Cohort Analysis Coupled Data Data Analyses Detection Diagnostic Neoplasm Staging Disease Early Detection Research Network Early Diagnosis Eastern Europe Enzymes Exhibits Funding Gender Genetic screening method Goals Histologic Histology Immune Individual International Knowledge Laboratories Legal patent Link Lipids Lung Adenocarcinoma Lung Neoplasms Malignant Neoplasms Malignant neoplasm of lung Methodology Methylation Mind Modality Modeling Molecular Monosaccharides Mutation Neoplasm Metastasis Newly Diagnosed Non-Small-Cell Lung Carcinoma Outcome Patients Performance Physicians Pilot Projects Plasma Polymers Polysaccharides Procedures Process Proteomics Publications Publishing Reagent Relative (related person)Reproducibility Research Design Risk Role Route Sample Size Sampling Seeds Serum Signal Transduction Site Small Cell Carcinoma Smoking Smoking Status Specificity Squamous cell carcinoma Staging Standardization Structure Symptoms Techniques Technology Technology Assessment Testing Time Tissues Universities University of Texas M D Anderson Cancer Center Validation Whole Blood analytical method anticancer research base biobank biosignature cancer cell cancer type case control cohort cost high risk improved interest lifestyle factors lung cancer screening model building neoplastic cell novel novel strategies public health relevance small molecule sugar tool tumor validation studies

项目摘要

DESCRIPTION (provided by applicant): Glycotransferases are sugar polymer-building enzymes that build glycans in a non-template driven fashion. Aberrant glycotransferase activity creates abnormal sugar polymers (glycans) which are a hallmark of essentially every known cancer. Abnormal glycans appear to facilitate the ability of cancer cells to avoid innate immune detection, detach from native sites, and traverse non-native tissues, allowing the cancer cells to metastasize. Glycotransferase enzymes build at specific glycan polymer branch-points (chain link sites) and, as a general rule, exhibit strict donor, acceptor, and linkage specificity. With these ideas in mind we developed the idea that specific monosaccharide-and-linkage-specific glycan polymer chain links (glycan "nodes", as we call them), if broken down, condensed and quantified from the pool of all glycan structures in a biological sample, could potentially serve a direct molecular surrogates of aberrant glycotransferase activity-in general contrast to traditiona glycomics approaches that look at whole, intact glycans. To enable this novel 'bottom-up' glycomics concept, an analytical methodology was devised and recently published that allows the simultaneous quantification of more than two dozen types of glycan nodes from N-, O-, and lipid-linked glycans relative to one another using only 10 microliters of blood serum or plasma. Samples from 3 independent lung cancer pilot study cohorts have now been studied, including 1) 31 stage IA lung adenocarcinoma patients and 31 individually paired age/gender/smoking matched controls from the NYU Lung Cancer Biomarker Center (an NCI EDRN site), 2) 30 newly diagnosed lung cancer patients and 29 age/gender/smoking status-matched controls from the INCO-COPERNICUS lung cancer in central and eastern Europe study, and 3) 24 lung cancer patients and 25 age/gender matched controls from a commercial biobank. Each cohort analyzed produced promising results with regard to distinguishing cases from controls; all were in general agreement about which glycan nodes are aberrantly produced in lung cancer patients. The goal of this project is to validate glycan node analysis as a tool for the early detection of lung cancer and as a classifier of lung tumor histology. Now that analytical and computational (data analysis) procedures for detection are locked down, this will be accomplished by carefully selecting and analyzing large sets of lung cancer patient samples, followed by well-defined biostatistical analysis for detection and multivariate model building for histology classification. Sample sets will include 1) an expanded set of 170 stage IA lung adenocarcinoma cases and 170 age/gender/smoking matched controls from the NYU Lung Cancer Biomarker Center, 2) 500 newly diagnosed cases and 500 controls from the INCO-COPERNICUS study, and 3) a similar set of 100 cases and 100 controls from ongoing studies at The University of Texas MD Anderson Cancer Center in Houston. This study will unambiguously define the role of blood-based glycan nodes as lung cancer biomarkers.